Latest:

Fat Pitch Financials

Special situation stocks and value investing

Stock Quote

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ascendis Pharma ADR (NQ: ASND )

110.58 +0.86 (+0.79%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ascendis Pharma ADR

< Previous 1 2 3 4 Next >
BridgeBio Soars 64% And Breaks Out After Smashing Expectations In A Dwarfism Study
The company is testing a drug for children with achondroplasia, a cause of dwarfism. 
Via Investor's Business Daily
Johnson & Johnson: Taking The Bull By The Horns?
Johnson & Johnson is rushing toward a patent cliff but a new shelf offering registration suggests itis gearing up for acquisitions. 
Via MarketBeat
Topics Intellectual Property Regulatory Compliance
Exposures Intellectual Property Legal Regulatory
Earnings Scheduled For February 16, 2023
Companies Reporting Before The Bell • RELX (NYSE:RELX) is estimated to report earnings for its Fiscal Year 2022. • Coca-Cola Europacific (NASDAQ:CCEP) is expected to report earnings for its Fiscal Year... 
Via Benzinga
Analyst Expectations for Ascendis Pharma's Future
 
Via Benzinga
Week In Review: Qitan Raises $101 Million For Nanopore Sequencing Devices
Qitan Technology, a Chengdu nanopore sequencing company, completed a $101 million Series C round to support its commercialized nanopore devices. Meanwhile, Japan’s Takeda was approved to launch... 
Via Talk Markets
Where Ascendis Pharma Stands With Analysts
 
Via Benzinga
What 9 Analyst Ratings Have To Say About Ascendis Pharma
 
Via Benzinga
Analyst Ratings for Ascendis Pharma
 
Via Benzinga
Ascendis Pharma's Program Hits Primary Goal In Children With Short-Limbed Dwarfism
 
Via Benzinga
Analyst Ratings for Ascendis Pharma
Ascendis Pharma (NASDAQ:ASND) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Why Infinity Pharmaceuticals Shares Tumbled Around 38%; Here Are 79 Biggest Movers From Yesterday
Gainers Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT) shares surged 113.8% to settle at $20.10 on Monday. Indivior PLC agreed to acquire Opiant Pharmaceuticals for $20.00 per share in cash, plus... 
Via Benzinga
6 Analysts Have This to Say About Ascendis Pharma
Ascendis Pharma (NASDAQ:ASND) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Expert Ratings for Ascendis Pharma
Within the last quarter, Ascendis Pharma (NASDAQ:ASND) has observed the following analyst ratings: 
Via Benzinga
Expert Ratings for Ascendis Pharma
Analysts have provided the following ratings for Ascendis Pharma (NASDAQ:ASND) within the last quarter: 
Via Benzinga
What 14 Analyst Ratings Have To Say About Ascendis Pharma
Within the last quarter, Ascendis Pharma (NASDAQ:ASND) has observed the following analyst ratings: 
Via Benzinga
Why Opiant Pharmaceuticals Shares Are Trading Higher By 115%? Here Are 53 Stocks Moving In Monday's Mid-Day Session
Gainers Freight Technologies, Inc. (NASDAQ: FRGT) shares surged 137% to $0.4901 after analysts at Chardan Capital initiated coverage of the stock with a $2.25 price target. 
Via Benzinga
Hasbro, Ascendis Pharma, Coinbase Global And Some Other Big Stocks Moving Lower On Monday
U.S. stocks traded mixed, with the Nasdaq gaining more than 50 points on Monday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Opiant Pharma (NASDAQ:OPNT) stock rose 118.3% to $20.74 during Monday's pre-market session. The market value of their outstanding shares is at $107.1 million. As per the press release, Q3... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 20, 2022
Upgrades 
Via Benzinga
Ascendis Seeks FDA Nod For TransCon PTH In Adults With Hypoparathyroidism
Ascendis Pharma (NASDAQ: ASND) has submitted a New Drug Application (NDA) to the U.S. Food & Drug Administration (FDA) for TransCon PTH, an investigational pro-drug designed to restore parathyroid... 
Via Benzinga
Oppenheimer Maintains Outperform Rating for Ascendis Pharma: Here's What You Need To Know
  Oppenheimer has decided to maintain its Outperform rating of Ascendis Pharma (NASDAQ:ASND) and lower its price target from $154.00 to $144.00. Shares of Ascendis Pharma are trading up 8.7% over the... 
Via Benzinga
Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Ascendis Slammed After Growth Hormone Drug Faces An Unexpected Challenge
Ascendis Pharma sells a treatment for children with insufficient growth hormone. 
Via Investor's Business Daily
The Daily Biotech Pulse: Novartis Prostate Cancer Drug Lands FDA Approval, Ligand Announces SPAC Deal To Spin Off Antibody Business, Lilly's Lung Cancer Therapy Hit With CRL
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
BofA Upgrades Ascendis Pharma After Promising TCP Phase 3 Data
Following Ascendis Pharma’s (NASDAQ: ASND) reporting of positive topline Phase III data for its PaTHway trial of TransCon PTH (TCP) in adults with hypoparathyroidism, the... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 15, 2022
Upgrades For Turquoise Hill Resources Ltd (NYSE:TRQ), BMO Capital upgraded the previous rating of Underperform to Market Perform. Turquoise Hill Resources earned $0.78 in the... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Erytech Pharma (NASDAQ:ERYP) stock rose 18.7% to $1.65 during Monday's pre-market session. The market value of their outstanding shares is at $51.1 million.... 
Via Benzinga
10 Biggest Price Target Changes For Monday
Wells Fargo raised the price target on Laredo Petroleum, Inc. (NYSE: LPI) from $72 to $113. Laredo Petroleum shares fell 2.8% to $71.00 in pre-market trading. 
Via Benzinga
Ascendis Pharma's Hypoparathyroidism Trial Meets Primary, Secondary Endpoints
Ascendis Pharma A/S (NASDAQ: ASND) announced topline data from its Phase 3 PaTHway Trial of TransCon PTH in adults with hypoparathyroidism (HP), a condition in... 
Via Benzinga
7 Biotech Stocks With Key Catalysts in March
These seven stocks have some key catalysts lined up for March with the potential to move their price actions in big ways. 
Via InvestorPlace
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.